“INHALED-POWDER” VACCINES “Shelf-Stable, Self-Inhaled, Powderized” VLP Vaccines TechnoVax and MannKind Corp. have combined their respective technologies to create a Powder Formulation of VLP Influenza Vaccine for Intrapulmonary Self-Delivery by Inhalation. Flu VLP’s FPDK Excipient Particle No Self- Refrigeration! Administered! CricketTM Inhalation Device
“INHALED-POWDER” VACCINES• Groundbreaking Concept: – Shelf-Stable vaccine requiring no refrigeration: Elimination of Cold Chain distribution (improved costs and inventory management, etc.). – Extended Shelf Live. – Allows for Self Administration, reducing cross infection risks at point of administration (limits propagation of virus in the event of a pandemic). – To be the First Company to launch an Inhaled Powder vaccine on the market.• Optimized Effectiveness: – Best Route of Immunization (mucosal surface - respiratory track) – Increased Patient Acceptance (inhaled vs. injection) – Pre-clinical studies in mice demonstrate Immunogenicity and Protective Efficacy (either inhaled powder or i.m. solubilized powder delivery methods).• Upmost Safety: – Proven VLP Technology. – Proven Inhaled technology. – No Infectious or Replicating agents
http://www.slideshare.net/technovax/technovax-presentation-at
